Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: Rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily

Xenobiotica

Volumn 28, Issue 3, 1998, Pages 235-268

  Lewis, D F V ^a   Dickins, M ^b   Weaver, R J ^c   Eddershaw, P J ^b   Goldfarb, P S ^d   Tarbit, M H ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Servier Research and Development   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 TERT BUTYLCYCLOHEXYL) 3 HYDROXY 1,4 NAPHTHOQUINONE; AMINO ACID; ATOVAQUONE; CYTOCHROME P450 ISOENZYME; DIAZEPAM; DICLOFENAC; DRUG; HEXOBARBITAL; IBUPROFEN; MEPHENYTOIN; METHYLPHENOBARBITAL; MOCLOBEMIDE; OMEPRAZOLE; PHENYTOIN; PROGUANIL; PROPRANOLOL; SULFAPHENAZOLE; TAMOXIFEN; TIENILIC ACID; TOLBUTAMIDE; WARFARIN;

AMINO ACID SEQUENCE; ARTICLE; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; MOLECULAR MODEL; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; MIXED FUNCTION OXYGENASES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; SEQUENCE ALIGNMENT; SPECIES SPECIFICITY; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SUBSTRATE SPECIFICITY;

BACTERIA (MICROORGANISMS);

EID: 0031934315     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598239542     Document Type: Article

References (64)

1. ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKUL, W., MEYER, U. A. and BIRKETT, D. J., 1993, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. British Journal of Clinical Pharmacology, 36, 521-530.
2. BAJPAI, M., ROSKOS, L. K., SHEN, D. D. and LEVY, R. H., 1996, Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metabolism and Disposition, 24, 1401-1403.
3. BIRKETT, D. J., ANDERSSON, T. and MINERS, J. O., 1996, Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. Methods in Enzymology, 272, 132-139.
4. DEGTYARENKO, K. N. and ARCHAKOV, A. I., 1993, Molecular evolution of P450 superfamily and P450-containing monoxygenase systems. FEBS Letters, 332, 1-8.
5. 180 → Cys) determines the polymorphism in cytochrome P450g (P4502C13) by altering protein stability. Journal of Biological Chemistry, 267, 2032-2037.
6. FUNCK-BRETANO, C., BECQUEMONT, L., LENEVEU, A., ROUX, A., JAILLON, P. and BEAUNE, P., 1997, Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. Journal of Pharmacology and Experimental Therapeutics, 280, 730-738.
7. FUNCK-BRENTANO, C., BOSCO, O., JACQZ-AIGRAIN, E., KEUNDJIAN, A. and JAILLON, P., 1992, Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clinical Pharmacology and Therapeutics, 51, 507-512.
8. GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEM, B. I., 1994, Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 33, 1743-1752.
9. GOLDSTEIN, J. A. and DE MORAIS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285-299.
10. GOTOH, O., 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry, 267, 83-90.
11. GRAHAM-LORENCE, S. and PETERSON, J. A., 1996, P450s: structural similarities and functional differences. FASEB Journal, 10, 206-214.
12. GRAM, L. F., GUENTERT, T. W., GRANGE, S., VISTISEN, K. and BROSEN, K., 1995, Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: a panel study. Clinical Pharmacology of Therapeutics, 57, 670-677.
13. HALL, S. D., GUENGERICH, F. P., BRANCH, R. A. and WILKINSON, G. R., 1987, Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 240, 216-222.
14. HANSCH, C., BJÖRKROTH, J. P. and LEO, A., 1987, Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. Journal of Pharmaceutical Sciences, 76, 663-687.
15. HANSCH, C. and LEO, A., 1979, Substituent Constants for Correlation Analysis in Chemistry and Biology (New York: Wiley).
16. HASEMANN, C. A., KURUMBAIL, R. G., BODDUPALLI, S. S., PETERSON, J. A. and DEISENHOFER, J., 1995, Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure, 3, 41-62.
17. HSU, M.-H., GRIFFIN, K. J., WANG, Y., KEMPER, B. and JOHNSON, E. F., 1993, A single amino acid substitution confers progesterone 6β-hydroxylase activity to rabbit cytochrome P450 2C3. Journal of Biological Chemistry, 268, 6939-6944.
18. IBEANU, G. C., GHANAYEM, B. I., LINKO, P., LI, L., PEDERSEN, L. G. and GOLDSTEIN, J. A., 1996, Identification of residues 99, 220 and 221 of human cytochrome P4502C19 as key determinants of omeprazole hydroxylase activity. Journal of Biological Chemistry, 271, 12496-12501.
19. IMAI, Y. and NAKAMURA, M., 1989, Point mutations at threonine-301 modify substrate specificity of rabbit liver microsomal cytochromes P-450 (laurate (ω-1)-hydroxylase and testosterone 16α-hydroxylase). Biochemical and Biophysical Research Communications, 158, 717-722.
20. INOUE, K., YAMAZAKI, H., IMIYA, K., AKASAKA, S., GUENGERICH, F. P. and SHIMADA, T., 1997, Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and s-mephenytoin 4′-hydroxylation activities in livers of japanese and caucasian populations. Pharmacogenetics, 7, 103-113.
21. JOHNSON, E. F., 1992, Mapping determinants of the substrate selectivity of P450 enzymes by site-directed mutagenesis. Trends in Pharmaceutical Sciences, 13, 122-126.
22. JONES, B. C., HAWKSWORTH, G., HORNE, V. A., NEWLANDS, A., MORSMAN, J., TUTE, M. S. and SMITH, D. A., 1996b, Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metabolism and Disposition, 24, 260-266.
23. JONES, B. C., HAWKSWORTH, G., HORNE, V., NEWLANDS, A., TUTE, M. and SMITH, D. A., 1993, Putative active site model for CYP2C9 (tolbutamide hydroxylase). British Journal of Clinical Pharmacology, 36, 143P-144P.
24. JONES, J. P., HE, M., TRAGER, W. F. and RETTIE, A. E., 1996a, Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metabolism and Disposition, 24, 1-6.
25. KAMINSKY, L. S., DE MORAIS, S. M. F., FALETTO, M. B., DUNBAR, D. A. and GOLDSTEIN, J. A., 1993, Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Molecular Pharmacology, 43, 234-239.
26. KARAM, W. G., GOLDSTEIN, J. A., LASKER, J. M. and GHANAYEM, B. I., 1996, Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metabolism and Disposition, 24, 1081-1087.
27. KORZEKWA, K. R. and JONES, J. P., 1993, Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics, 3, 1-18.
28. KRONBACH, T. and JOHNSON, E. F., 1991, An inhibitory monoclonal antibody binds in close proximity to a determinant for substrate binding in cytochrome P450IIC5. Journal of Biological Chemistry, 266, 6215-6220.
29. KRONBACH, T., KEMPER, B. and JOHNSON, E. F., 1991, A hypervariable region of P450IIC5 confers progesterone 21-hydroxylase activity to P450IIC1. Biochemistry, 30, 6097-6102.
30. KRONBACH, T., LARABEE, T. M. and JOHNSON, E. F., 1989, Hybrid cytochromes, P-450 identify a substrate binding domain in P-450IIC5 and P-450IIC4. Proceedings of the National Academy of Sciences, USA, 86, 8262-8265.
31. KUPFER, A. and BRANCH, R. A., 1985, Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clinical Pharmacology and Therapeutics, 38, 414-418.
32. LAKE, B. G. and LEWIS, D. F. V., 1996, The CYP4 family. In Cytochromes P450: Metabolic and Toxicological Aspects edited by C. Ioannides (Boca Raton: CRC Press, chapter 11.
33. LEVITT, M. and PERUTZ, M. F., 1988, Aromatic rings act as hydrogen bond acceptors. Journal of Molecular Biology, 201, 751-754.
34. bm3). Xenobiotica, 25, 333-366.
35. LEWIS, D. F. V., 1996a, Cytochromes P450: Structure, Function and Mechanism (London: Taylor & Francis).
36. LEWIS, D. F. V., 1996b, Molecular modelling of mammalian cytochromes P450 with specific substrates and inhibitors. In Cytochromes P450: Metabolic and Toxicological Aspects, edited by C. Ioannides (Boca Raton, CRC Press), chapter 14.
37. LEWIS, D. F. V. and LAKE, B. G., 1995, Molecular modelling of members of the CYP2A subfamily: application to studies of enzyme specificity, Xenobiotica, 25, 585-598.
38. LEWIS, D. F. V. and LAKE, B. G., 1996, Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site residues, Xenobiotica, 26, 723-753.
39. LOPEZ-GARCIA, M. P., DANSETTE, P. M., VALADON, P., AMAR, C., BEAUNE, P. H., GUENGERICH, F. P. and MANSUY, D., 1993, Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies: oxidative activation of tienilic acid by cytochromes P-4502C9 and 2C10, European Journal of Biochemistry, 213, 223-232.
40. MANCY, A., BROTO, P., DIJOLS, S., DANSETTE, P. M. and MANSUY, D., 1995, The substrate binding site of human liver cytochrome P4502C9: an approach using designed tienilic acid derivatives and molecular modelling, Biochemistry, 34, 10365-10375.
41. MANCY, A., DIJOLS, S., POLI, S., GUENGERICH, F. P. and MANSUY, D., 1996, Interaction of sulfaphenazole derivatives with human liver cytochromes P4502C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9, Biochemistry, 35, 16205-16212.
42. MINERS, J. O. and BIRKETT, D. J., 1996, Use of tolbutamide as a substrate probe for human hepatic cytochrome P4502C9, Methods in Enzymology, 272, 139-145.
43. MORSMAN, J. M., SMITH, D. A., JONES, B. C. and HAWKSWORTH, G. M., 1995, Role of hydrogen-bonding in substrate structure-activity relationships for CYP2C9. In Proceedings of the 4th International ISSX Meeting, Seattle, Washington, USA, 27-31 August, p. 259.
44. NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., OKUDA, K. and NEBERT, D. W., 1993, The P-450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature, DNA and Cell Biology, 12, 1-51.
45. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., GUNSALUS, I. C. and NEBERT, D. W., 1996, CYP450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics, 6, 1-42.
46. OHGIYA, S., KOMORI, M, OHI, H., SHIRAMATSU, K., SHINRIKI, N. and KAMATAKI, T., 1992, Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity, Biochemistry International, 27, 1073-1081.
47. RAVICHANDRAN, K. G., BODDUPALLI, S. S., HASEMANN, C. A., PETERSON, J. A. and DEISENHOFER, J., 1993, Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450s, Science, 261, 731-736.
48. REKKER, R. F., TER LAAK, A. M. and MANNHOLD, R., 1993, On the reliability of calculated log P values: Rekker, Hansch/Leo and Suzuki approach, Quantitative Structure-Activity Relationships, 12, 152-157.
49. RETTIE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. D., AOYAMA, T., GELBOIN, H. V., GONZALEZ, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions, Chemical Research in Toxicology, 5, 54-59.
50. RICHARDSON, T. H. and JOHNSON, E. F., 1994, Alterations of the regiospecificity of progesterone metabolism by the mutagenesis of two ken amino acid residues in rabbit cytochrome P450 2C3v, Journal of Biological Chemistry, 269, 23937-23943.
51. SANGSTER, J., 1989, Octanol-water partition coefficients of simple organic compounds, Journal of Physical and Chemical Reference Data, 18, 1111-1229.
52. SMITH, D. A. and JONES, B. C., 1992, Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes, Biochemical Pharmacology, 44, 2089-2098.
53. STRAUB, P., JOHNSON, E. F. and KEMPER, B., 1993b, Hydrophobic side chain requirements for lauric acid and progesterone hydroxylation at amino acid 113 in cytochrome P450 2C2, a potential determinant of substrate specificity, Archives of Biochemistry and Biophysics, 306, 521-527.
54. STRAUB, P., LLOYD, M., JOHNSON, E. F. and KEMPER, B., 1993a, Cassette mutagenesis of a potential substrate recognition region of cytochrome P450 2C2, Journal of Biological Chemistry, 268, 21997-22003.
55. SUZUKI, T. and KUDO, Y., 1990, Automatic log P estimation based on combined additive modeling methods, Journal of Computer-Aided Molecular Design, 4, 155-198.
56. VERONESE, M. E., DOECKE, C. J., MACKENZIE, P. I., MCMANUS, M. E., MINERS, J. O., REES, D. L. P., GASSER, R., MEYER, V. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily, Biochemical Journal, 289, 533-538.
57. WACHENFELDT, C. V. and JOHNSON, E. F., 1995, Structures of eukaryotic cytochrome P450 enzymes. In Cytochrome P450, edited by P. R. Ortiz de Montellano (New York: Plenum), pp. 183-223.
58. WEAVER, R. J., DICKINS, M., WALLER, S. J., CHAMBERS, J. M., MORLEY, T. J. and BURKE, M. D., 1995, Proguanil metabolism in hepatic microsomes and isolated hepatocytes from animals and man, and the effect of Atovaquone and CYP inhibitors. In Proceedings of the 4th International ISSX Meeting, Seattle, Washington, USA, 27-31 August, p. 295.
59. WEDLAND, P. J. and WILKINSON, G. R., 1996, In vivo and in vitro measurement of CYP2C19 activity, Methods in Enzymology, 272, 105-114.
60. 14C] tamoxifen to liver microsomes and the forms of cytochrome P450 involved, Biochemical Pharmacology, 49, 1035-1042.
61. WIENKERS, L. C., WURDEN, C. J., STORCH, E., KUNZE, K. L., RETTIE, A. E. and TRAGER, W. F., 1996, Formation of (R)-8-hydroxywarfarin in human liver microsomes, Drug Metabolism and Disposition, 24, 610-614.
62. WISEMAN, H. and LEWIS, D. F. V., 1996, The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anticarcinogenic/carcinogenic actions, Carcinogenesis, 17, 1357-1360.
63. WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. and VAN DEN BRANDEN, M., 1993, Isolation and characterization of human liver cytochrome P4502C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation, Archives of Biochemistry and Biophysics, 306, 240-245.
64. YAMAZAKI, S., SATO, K., SUHARA, K., SAKAGUCHI, M., MIHARA, K. and OMURA, T., 1993, Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s, Journal of Biochemistry (Tokyo), 114, 652-657.